Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 1 , Pages 3-12 , February 2010

Diagnosis and staging in gastrointestinal lymphoma

  • Henk Boot (Gastroenterologist)

      Affiliations

    • Corresponding Author InformationTel.: +31 205122566; fax: +31 205122572.

References 

  1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994
  2. Johnston A, Salles G. Prognostic systems for lymphomas. Hematol Oncol Clin North Am. 2008;22:839–861
  3. Musshoff K. Klinische Stadieneinteilung der Nicht-Hodgkin lymphome. Strahlentherapie. 1977;153:218–221
  4. Otter R, Gerrits WBJ, vd Sandt MM, et al. Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer. 1989;25:1203–1210
  5. D'Amore F, Brincker H, Grønbaek K, et al. Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol. 1994;12:1673–1684
  6. Ullrich A, Fischbach W, Blettner M. Incidence of gastric B-cell lymphomas: a population-based study in Germany. Ann Oncol. 2002;13:1120–1127
  7. Andrews CN, Gill MJ, Urbanski SJ, et al. Changing epidemiology and risk factors for gastrointestinal Non-Hodgkin's Lymphoma: population-based study. Am J Gastroenterol. 2008;103:1762–1769
  8. Capelle LG, de Vries AC, Looman CW, et al. Gastric Malt lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008;44:2470–2476
  9. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52:1410–1416
  10. In:  Isaacson PG,  Norton AJ editor. Extranodal lymphomas. Edinburgh: Churchill Livingstone; 1994;p. 1–329
  11. Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin's lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997;8:727–737
  12. Zucca E. Extranodal lymphoma: a reappraisal. Ann Oncol. 2008;19(Suppl. 4):iv70–iv80
  13. Rohatiner A, D'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397–400
  14. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organisation classification of hematological malignacy report of the Clinical Advisory Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193–207
  15. In:  Swerdlow SH,  Campo E,  Harris NL editor. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed.. Lyon (France): IARC Press; 2008;
  16. Jaffe ES, Harris NL, Stein H, et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112:4384–4399
  17. Krol AD, le Cessie S, Snijder S, et al. Primary extranodal non-Hodgkin's lymphoma: the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol. 2003;14:131–139
  18. Gospodarowicz MK, Ferry JA, Cavalli F, et al. Unique aspects of primary extranodal lymphomas. In:  Mauch PM,  Armitage JO,  Harris NL editor. Non Hodgkin's lymphomas. Philadelphia, PA: Lipincott Williams & Wilkins; 2003;p. 685–707
  19. May A, Nachbar L, Pohl J, et al. Endoscopic interventions in the small bowel using double balloon enteroscopy: feasibility and limitations. Am J Gastroenterol. 2007;102:527–535
  20. Kobayashi K, Katsumata T, Saigenji K. Clinical usefulness of single-balloon enteroscopy in the diagnosis and treatment of small-intestinal diseases. In:  Niwa H editors. New challenges in gastrointestinal endoscopy. Springer; 2008;p. 243–250
  21. Flieger D, Keller J, May A, et al. Capsule endoscopy in gastrointestinal lymphomas. Endoscopy. 2000;37:1174–1180
  22. Boot H. In: Thesis  editors. Gastric MALT-Lymphoma. Studies on diagnosis, pathogenesis and treatment. Amsterdam: Thesis Publishers; 1997;
  23. Fischbach W, Dragosics B, Kolve-Goebeler M-E, et al. for the German–Austrian gastrointestinal lymphoma study group. Primary gastric B-cell lymphoma: results of a prospective multicenter study. Gastroenterology. 2000;119:1191–1202
  24. De Jong D, Boot H, van Heerde P, et al. Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology. 1997;112:1466–1474
  25. Boot H, de Jong D. Diagnosis, treatment decisions, and follow-up in primary gastric lymphoma. Gut. 2002;51:621–622
  26. Fischbach W. Gastric mucosa-associated lymphoid tissue lymphoma: a challenge for endoscopy. Gastrointest Endosc. 2008;68:632–634
  27. Seifert E, Schulte F, Weismüller J, et al. Endoscopic and bioptic diagnosis of malignant non-Hodgkin's lymphoma of the stomach. Endoscopy. 1993;25:497–501
  28. Taal BG, Boot H, van Heerde P, et al. Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept. Gut. 1996;39:556–561
  29. Mehra M, Agarwal B. Endoscopic diagnosis and staging of mucosa-associated lymphoid tissue lymphoma. Curr Opin Gastroenterol. 2008;24:623–626
  30. Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of the stomach: diagnostic pitfalls and management. Ann Oncol. 2008;19:1992–1999
  31. Kolve M, Fischbach W, Greiner A, et al. Differences in endoscopic and clinicopathological features of primary and secondary gastric non-Hodgkin's lymphoma. Gastrointest Endosc. 1999;49:307–315
  32. Ono S, Kato M, Ono Y, et al. Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment. Gastrointest Endosc. 2008;68:624–631
  33. Liu H, Ye H, Ruskoné-Fourmestraux A, et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122:1286–1294
  34. Rosenwald A, Wright G, Chan WC, et al. for the Lymphoma/Leukemia Molecular Profiling Project The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947
  35. Hans CP, Weissenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282
  36. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterised by host inflammatory response. Blood. 2005;105:1851–1861
  37. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185–197
  38. Hoster E, Dreyling M, Klapper W, et al. for the German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood. 2008;111:558–565Erratum in: Blood. 2008;111:5761
  39. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209–1213
  40. Cellier C, Delabesse E, Helmer C, et al. Refractrory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. A French coeliac disease study group. Lancet. 2000;356:203–208
  41. Verbeek WHM, Schreurs MWJ, Visser OJ, et al. Novel approaches in the management of refractory coeliac disease. Exp Rev Clin Immunol. 2008;4:205–219
  42. Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory coeliac disease: comparison of type I with type II. Gastroenterology. 2009;136:81–90
  43. Lehours P, Ménard A, Dupouy S, et al. Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Infect Immun. 2004;72:880–888
  44. Lehours P, Ruskoné-Fourmestraux A, Lavergne A, et al. for the Groupe d'Etude des Lymphomes Digestifs (GELD) for the Fédération Francaise de Cancérologie Digestive (FFCD) Am J Gastroenterol. 2003;98:291–295
  45. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev. 2007;20:280–322
  46. Eck M, Greiner A, Schmauβer B, et al. Evaluation of Helicobacter pylori in gastric MALT-type lymphoma: differences between histologic and serologic diagnosis. Mod Pathol. 1999;12:1148–1151
  47. De Jong D, Aleman BMP, Taal BG, et al. Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Ann Oncol. 1999;10:275–280
  48. Cheson BD, Pfistner B, Juweid ME, et al. for the International Harmonisation Project on Lymphoma Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586
  49. Cheson BD. Staging and evaluation of the patient with lymphoma. Hematol Oncol Clin North Am. 2008;22:825–837
  50. Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B-cells: a model of antigen driven lymphoproliferation. Blood. 2006;107:3034–3044
  51. Wöhrer S, Troch M, Streubel B, et al. MALT lymphoma in patients with autoimmune disease: a comparative analysis of characteristics and clinical course. Leukemia. 2007;21:1812–1818
  52. Boveri E, Arcaini L, Merli M, et al. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol. 2009;20:129–136
  53. Raderer M, Vorbeck F, Formanek M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT-type)-lymphoma. Br J Cancer. 2000;83:454–457
  54. Raderer M, Wöhrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006;24:3136–3141
  55. Schreuder MI, Hoeve MA, Groothuis L, et al. Monitoring gastric lymphoma in peripheral blood by quantitative IgH allele-specific oligonucleotide real-time PCR and API2-MALT1 PCR. Br J Haematol. 2005;131:619–623
  56. Siakantaris MP, Pangalis GA, Dimitriadou E, et al. Early-stage gastric MALT lymphoma: is it a truly localised disease?. Oncologist. 2009;14:148–154
  57. Liu H, Ruskoné-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39–40
  58. Bhandari S, Shim CS, Kim JH, et al. Usefulness of three-dimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: a comparison with conventional endoscopy, EUS, and histopathology. Gastrointest Endosc. 2004;59:619–626
  59. Chen CY, Hsu JS, Wu DC, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT–correlation with surgical and histopathologic results. Radiology. 2007;242:472–482
  60. Hargunani R, Maclachlan J, Kaniyur S, et al. Cross-sectional imaging of gastric neoplasia. Clin Radiol. 2009;64:420–429
  61. Kösling S, Steingrüber K, Heywang-Köbrunner SH, et al. Spiral CT of the stomach in hypotonia. Eur Radiol. 1995;5:255–258
  62. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body Positron Emission Tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin lymphoma has higher diagnostic and prognostic value than classical Computed Tomography scan imaging. Blood. 1999;94:429–433
  63. Isai CR, Lu P, Blaufox MD. A metaanalysis of 18F-2deoxy-2fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104:1066–1074
  64. Juweid ME, Sroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonisation Project in lymphoma. J Clin Oncol. 2007;25:571–578
  65. Terasawa T, Lau J, Bordet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advaced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906–1914
  66. Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79:205–209
  67. Enomoto K, Hamada K, Inohara H, et al. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings. Ann Nucl Med. 2008;22:261–267
  68. Wotherspoon A, Doglioni C, Isaacson PG. Low-grade gastric B-cell lymphoma of mucosa associated lymphoid tissue (MALT): a multifocal disease. Histopathology. 1992;20:29–34
  69. Sackmann M, Morgner A, Rudolph B, et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology. 1997;113:1087–1090
  70. Du MQ, Diss TC, Dogan A, et al. Clone-specific PCR reveals wide dissemination of gastric MALT lymphoma to the gastric mucosa. J Pathol. 2000;192:488–493
  71. Dabaja BS, Ha CS, Wilder RB, et al. Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer J. 2003;9:321–324
  72. De Boer JP, Hiddink RF, Raderer M, et al. Dissemination patterns in non-gastric MALT lymphoma. Haematologica. 2008;93:201–206
  73. Palazzo L, Roseau G, Ruskone-Fourmestraux A, et al. Endoscopic ultrasonography in the local staging of primary gastric lymphoma. Endoscopy. 1993;25:502–508
  74. Caletti G, Ferrari A, Brocchi E, et al. Accuracy of endoscopic ultrasonography in the diagnosis and staging of gastric cancer and lymphoma. Surgery. 1993;113:14–27
  75. Ruskoné-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut. 2001;48:297–303
  76. Fischbach W, Goebeler-Kolve ME, Greiner A. Diagnostic accuracy of EUS in the local staging of primary gastric lymphoma: results of a prospective, multicenter study comparing EUS with histopathologic stage. Gastrointest Endosc. 2002;56:696–700
  77. Lévy M, Hammel P, Lamarque D, et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. Gastrointest Endosc. 1997;46:328–333
  78. Püspök A, Raderer M, Chott A, et al. Endoscopic ultrasound in the follow up and response assessment of patients with primary gastric lymphoma. Gut. 2002;51:691–694
  79. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas. Gut. 2003;52:912–913
  80. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992;102:1628–1638
  81. Park SR, Lee JS, Kim CG, et al. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer. 2008;112:2368–2376
  82. Copie-Bergman C, Locher C, Levy M, et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?. Ann Oncol. 2005;16:1232–1236
  83. Raderer M, Streubel B, Wöhrer S, et al. Metachronous gastric MALT lymphoma and early gastric cancer. Ann Oncol. 2006;17:724
  84. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. for the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut. 2003;52:1656
  85. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. for the EGILS (European Gastro-Intestinal Lymphoma Study) Group Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut. 2007;56:1685–1687
  86. Zinzani PL, Magagnoli M, Ascani S, et al. Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: clinical and therapeutic features of 24 localised patients. Ann Oncol. 1997;8:883–886

PII: S1521-6918(09)00156-5

doi: 10.1016/j.bpg.2009.12.003

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 1 , Pages 3-12 , February 2010

Article Tools